Literature DB >> 31801085

Liver Soluble Epoxide Hydrolase Regulates Behavioral and Cellular Effects of Chronic Stress.

Xi-He Qin1, Zhou Wu2, Jing-Hua Dong3, Yuan-Ning Zeng3, Wen-Chao Xiong2, Ce Liu3, Meng-Yao Wang3, Min-Zhen Zhu3, Wen-Jun Chen3, Yuan Zhang3, Qi-Yuan Huang3, Xin-Hong Zhu4.   

Abstract

Major depression is a serious global health concern; however, the pathophysiology underlying this condition remains unclear. While numerous studies have focused on brain-specific mechanisms, few have evaluated the role of peripheral organs in depression. Here, we show that the liver activates an intrinsic metabolic pathway that can modulate depressive-like behavior. We find that chronic stress specifically increases the protein levels of monomeric and oligomeric soluble epoxide hydrolase (sEH), a key enzyme in epoxyeicosatrienoic acid (EET) signaling, in the liver. Hepatic deletion of Ephx2 (which encodes sEH) results in antidepressant-like effects, while the hepatic overexpression of sEH induces depressive phenotypes. The activity of sEH in hepatocytes modulates the plasma levels of 14,15-EET, which then interacts with astrocytes in the medial prefrontal cortex to mediate the effects of hepatic Ephx2 deletion. These results suggest that targeting mechanisms underlying the hepatic response to stress would increase our therapeutic options for the treatment of depression.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  14,15-EET; 14,15-epoxyeicosatrienoic acid; biomarkers; liver; major depressive disorder; oligomerization; soluble epoxide hydrolase; therapy

Year:  2019        PMID: 31801085     DOI: 10.1016/j.celrep.2019.11.006

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  9 in total

1.  An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Anamitra Ghosh; Michele M Comerota; Debin Wan; Fading Chen; Nicholas E Propson; Sung Hee Hwang; Bruce D Hammock; Hui Zheng
Journal:  Sci Transl Med       Date:  2020-12-09       Impact factor: 17.956

Review 2.  Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders.

Authors:  Jiajing Shan; Kenji Hashimoto
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

Review 3.  Soluble Epoxide Hydrolase and Diabetes Complications.

Authors:  Natasha Z Anita; Walter Swardfager
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

4.  14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.

Authors:  Wenjun Chen; Mengyao Wang; Minzhen Zhu; Wenchao Xiong; Xihe Qin; Xinhong Zhu
Journal:  J Neurosci       Date:  2020-09-24       Impact factor: 6.167

5.  Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis.

Authors:  Jiancheng Zhang; Yunfei Tan; Lijia Chang; Bruce D Hammock; Kenji Hashimoto
Journal:  J Affect Disord       Date:  2020-04-08       Impact factor: 4.839

Review 6.  Epoxy Fatty Acids Are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation.

Authors:  Cindy McReynolds; Christophe Morisseau; Karen Wagner; Bruce Hammock
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  The Ghrelin/Growth Hormone Secretagogue Receptor System Is Involved in the Rapid and Sustained Antidepressant-Like Effect of Paeoniflorin.

Authors:  Yuan Zhang; Min-Zhen Zhu; Xi-He Qin; Yuan-Ning Zeng; Xin-Hong Zhu
Journal:  Front Neurosci       Date:  2021-02-16       Impact factor: 4.677

8.  Metabolomics changes in brain-gut axis after unpredictable chronic mild stress.

Authors:  Qiuyue Xu; Mingchen Jiang; Simeng Gu; Xunle Zhang; Guangkui Feng; Xianjun Ma; Shijun Xu; Erxi Wu; Jason H Huang; Fushun Wang
Journal:  Psychopharmacology (Berl)       Date:  2022-02-08       Impact factor: 4.530

9.  Soluble Epoxide Hydrolase Is Associated with Postprandial Anxiety Decrease in Healthy Adult Women.

Authors:  Nhien Nguyen; Christophe Morisseau; Dongyang Li; Jun Yang; Eileen Lam; D Blake Woodside; Bruce D Hammock; Pei-An Betty Shih
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.